PCSK9 and metabolic syndrome: In this context, further studies, including those with newly drugs such as monoclonal antibody against PCSK9 and synthetic small RNA that interferes PCSK9 transcription46,47, could contribute to acquire a more detailed understanding of the link between PCSK9 and EAT volume and to determine its contribution to dyslipidemia and increased CVD risk associated with T1D.